ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.869,36
0,78%
S&P 500
5.308,15
1,17%
Dow Jones
39.908,00
0,88%
Euro vs US Dollar
1,08857
0,66%
Bitcoin
66.042,54
7,29%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Adial Pharmaceuticals Inc (ADIL)

  7. Adial Pharmaceuticals Inc (ADIL) News

ADIL

Adial Pharmaceuticals (ADIL)

Adial Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ADIL
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202414h30GlobeNewswire Inc.Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ADILAdial Pharmaceuticals Inc
14/05/202423h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADILAdial Pharmaceuticals Inc
22/04/202414h30GlobeNewswire Inc.Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeNASDAQ:ADILAdial Pharmaceuticals Inc
10/04/202414h30GlobeNewswire Inc.Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderNASDAQ:ADILAdial Pharmaceuticals Inc
02/04/202414h30GlobeNewswire Inc.Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business UpdateNASDAQ:ADILAdial Pharmaceuticals Inc
02/03/202401h00GlobeNewswire Inc.Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsNASDAQ:ADILAdial Pharmaceuticals Inc
28/02/202415h30GlobeNewswire Inc.Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeNASDAQ:ADILAdial Pharmaceuticals Inc
14/02/202421h22Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADILAdial Pharmaceuticals Inc
13/02/202415h15GlobeNewswire Inc.Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark OfficeNASDAQ:ADILAdial Pharmaceuticals Inc
25/01/202422h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ADILAdial Pharmaceuticals Inc
25/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ADILAdial Pharmaceuticals Inc
18/01/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
18/01/202414h30GlobeNewswire Inc.Adial Announces Appointment of Tony Goodman as Chief Operating OfficerNASDAQ:ADILAdial Pharmaceuticals Inc
16/01/202422h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
12/01/202422h51Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ADILAdial Pharmaceuticals Inc
20/12/202315h00GlobeNewswire Inc.Adial Pharmaceuticals Receives Final Reimbursement Payment from AdovateNASDAQ:ADILAdial Pharmaceuticals Inc
12/12/202322h36Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ADILAdial Pharmaceuticals Inc
08/12/202317h08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ADILAdial Pharmaceuticals Inc
29/11/202322h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
29/11/202322h05GlobeNewswire Inc.Adial Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementNASDAQ:ADILAdial Pharmaceuticals Inc
28/11/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
24/11/202315h24Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ADILAdial Pharmaceuticals Inc
20/11/202313h46Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ADILAdial Pharmaceuticals Inc
20/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ADILAdial Pharmaceuticals Inc
14/11/202323h02GlobeNewswire Inc.Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ADILAdial Pharmaceuticals Inc
08/11/202322h05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ADILAdial Pharmaceuticals Inc
06/11/202312h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
31/10/202313h30GlobeNewswire Inc.Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine ConferenceNASDAQ:ADILAdial Pharmaceuticals Inc
30/10/202322h24Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ADILAdial Pharmaceuticals Inc
30/10/202322h18Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ADILAdial Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ADIL

Kürzlich von Ihnen besucht

UNSW
STBUETH
Stobox Token
BIT
F11215
Vontobel Financial Produ...
BIT
UB78F3
Unicredit Bank
EU
LIG
Lisgrafica
BIT
I08390
Intesa Sanpaolo
COIN
YPIEETH
PieDAO Yearn Ecosystem Pie
COIN
FANZUST
FanChain
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten